



(51) International Patent Classification:

A61K 38/03 (2006.01) *A61K 33/06* (2006.01)
A61K 39/39 (2006.01) *A61P 25/28* (2006.01)

(21) International Application Number:

PCT/EP2015/059337

(22) International Filing Date:

29 April 2015 (29.04.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/985,710 29 April 2014 (29.04.2014) US
14166355.9 29 April 2014 (29.04.2014) EP

(71) Applicant: **AFFIRIS AG** [AT/AT]; Karl-Farkas-Gasse 22,
A-1030 Vienna (AT).

(72) Inventors: **MANDLER, Markus**; c/o AFFIRIS AG, Karl-
Farkas-Gasse 22, A-1030 Vienna (AT). **SCHNEEBER-
GER, Achim**; c/o AFFIRIS AG, Karl-Farkas-Gasse 22, A-
1030 Vienna (AT). **MATTNER, Frank**; c/o AFFIRIS AG,
Karl-Farkas-Gasse 22, A-1030 Vienna (AT). **SCHMIDT,
Walter**; c/o AFFIRIS AG, Karl-Farkas-Gasse 22, A-1030
Vienna (AT).

(74) Agent: **SONN & PARTNER PATENTANWÄLTE**;
Riemergasse 14, 1010 Vienna (AT).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

— with sequence listing part of description (Rule 5.2(a))

(54) Title: TREATMENT AND PREVENTION OF ALZHEIMER'S DISEASE (AD)

(57) Abstract: Disclosed is a method for the treatment of AD, wherein an immune stimulating pharmaceutical composition compris-
ing an aluminium salt is administered to a patient having AD or having a risk to develop AD in an effective amount.



WO 2015/165964 A1

Treatment and prevention of Alzheimer's Disease (AD)

The present invention relates to means and methods for the treatment and the prevention of dementias associated with β -amyloid deposition, preferably Alzheimer's Disease (AD).

Various dementias are characterized by the aberrant accumulation of Amyloid- β polypeptides ($A\beta$) resulting in β -amyloid deposition. The most prominent form of β -Amyloidoses is AD. Other examples include but are not limited to Dementia with Lewy bodies and Dementia in Down syndrome.

AD is the most prevalent neurodegenerative disorder currently affecting 28 million people worldwide. It typically presents with a characteristic amnesic dysfunction associated with other cognitive-, behavioural- and neuropsychiatric changes. AD is characterized by the abnormal accumulation of intra- and extracellular amyloid deposits - closely associated with extensive astrogliosis and microgliosis as well as dystrophic neurones and neuronal loss. These amyloid deposits mainly consist of $A\beta$ -peptides $A\beta_{40}$ and $A\beta_{42}$ derived from the Amyloid Precursor Protein (APP; gi:112927), which is expressed on various cell types in the nervous system. $A\beta$ peptides are considered to be directly involved in the pathogenesis and progression of AD.

Besides amyloid deposits, neurofibrillary tangles (NFT) embody the second characteristic neuropathological hallmark of AD, first described by Alois Alzheimer. These lesions occur in the hippocampus, amygdala association cortices, and certain subcortical nuclei. NFTs are located in the cytoplasm of neurons and are composed of hyperphosphorylated tau protein. Tau is an axonal, microtubule binding protein that promotes microtubule assembly and stability under normal conditions. Hyperphosphorylation of Tau results in loss of microtubule association and subsequent disassembly of microtubules, which in turn leads to an impairment of axonal transport and subsequent axonal and neuronal degeneration. It is still unclear whether tau hyperphosphorylation and tangle formation are a cause or a consequence of AD.

Besides amyloid and Tau/hyperphosphorylated Tau pathology, neuroinflammation can be considered as the third integral pillar of pathophysiologic changes causing neurodegeneration in AD. The neuroinflammatory phenotype in AD is characterized by robust and widespread activation of microglia and astrocytes in the affect-

ed brain regions, resulting in endogenous expression of pro-inflammatory cytokines, cell adhesion molecules, and chemokines. These changes are thought to result from glial reaction to events related to ongoing toxicity elicited by amyloid and Tau/hyperphosphorylated Tau and their mediators.

It is currently believed that one potential treatment strategy for AD and related disorders could be based on immunotherapy to prevent or reduce the accumulation of neurotoxic agents like A β or Tau/hyperphosphorylated Tau.

Various active and passive treatment strategies targeting Tau/hyperphosphorylated Tau led to a reduction of Tau/hyperphosphorylated Tau deposition and associated neuropathological changes in animal models, however, no positive data in human AD patients are available so far. Quite in contrast, there have been a significant number of clinical trial failures in the most recent past: Results "from the Phase III clinical trials of two monoclonal antibodies – bapineuzumab and solanezumab – that target amyloid- β indicated little clinical benefit of immunological attack on amyloid- β at the dementia stage of sporadic disease" (Aisen et al., Nat. Rev. Drug Disc. 12 (2013), 324-325; Mullard, Nat. Rev. Drug Disc. 11 (2012), 657-660). Also other studies of hypothesis-driven candidate disease modifiers "such as anti-inflammatory drugs, secretase inhibitors and modulators, hormonal therapies, statins and other drugs have been disappointing", including the "clinical failure of the two leading γ -secretase inhibitors, semagacestat [...] and avagacestat" (Aisen et al., 2013; Mullard, 2012). Commentators have termed this poor clinical outcome of AD clinical trials as "the culmination of a 'lost decade' in Alzheimer's disease therapeutic trials, with no substantial success since the approval of memantine" (Aisen et al., 2013). In the course of this development, the US-FDA also amended the rules for approving new treatments for AD and recommended the use of AD specific biomarkers, such as radiologic biomarkers using PET (positron emission tomography) scans (Kozauer et al., N. Engl. J. Med. 368 (2013), 1170-1171).

WO 94/16327 A1 discloses therapeutic agents that involve an "amyloid protein ion channel". However, this concept of amyloid protein ion channel of WO 94/16327 A1 was not further prosecuted and was finally challenged scientifically (Sokolov et al., J.

Gen. Physiol. 128 (2006), 637-647; commentary by Eliezer, J. Gen. Physiol. 128 (2006), 631-633).

In addition, the teachings of WO 94/16327 A1 imply an active interaction of Al-ions with potential A β -Ion channels in vivo, thereby inhibiting these channels. Thus, in order for aluminium to full fill this task, the compound has to reach the brain as the site of activity in the suggested concentrations. In the human brain normal levels of aluminium range from 0.25 to 0.75 mg/kg wet weight, with the grey matter (mainly responsible for regulating cognitive function affected in AD) containing about twice the concentration found in the white matter (The EFSA Journal (2008) 754, 24-88; Annex to the EFSA Journal (2008) 754, 1-34 opinion "Safety of aluminium from dietary intake"). There is evidence that with increasing age, aluminium concentrations may even increase in the human brain tissue. Similarly, several studies also indicate that brains derived from AD patients show higher Al-levels than healthy control brains (reviewed in Yokel, NeuroToxicology 21 (2000), 813-828). Thus the suggested therapeutically active Al concentration is already present in healthy and diseased brain (in the range of the intended use-formulation as described in WO 94/16327 A1, claim 12: 0.01-10mg/kg). In addition, bioavailability of Al in brain after parenteral and oral uptake is kept low relying on actively regulated, highly efficient influx/efflux mechanisms and requires high peripheral doses to reach suggested therapeutic cerebral concentrations. It is therefore without plausible scientific basis that an additional increase in peripheral Al would lead to additional cerebral Al levels required for exerting direct, therapeutically beneficial effects without eliciting potential toxic effects.

Furthermore, Figure 7 and 8 of this application disclose that topically applied aluminium-oxyhydroxide is able to lower cognitive decline significantly in an APP-transgenic model for Alzheimer's disease (Tg2576) without significantly changing cerebral A β levels. This is implying an APP/A β independent mechanism underlying beneficial functional effects exerted by aluminium-oxyhydroxide in this AD model.

WO 99/27944 A1 discloses AD vaccines being essentially based on the presence of an agent effective to induce an immunogenic response against A β . WO 2011/120924 A1 refers to an A β vaccine,

which is essentially based on A β 1-6 peptide bound to a virus-like particle. WO 2006/005707 A2, WO 2009/149486 A2 and WO 2009/149485 A2 disclose A β mimotope peptides for use in vaccines for the prevention and treatment of AD.

Heneka et al. (Nature, 493 (7434) (2012): 674-678) suggest the treatment of AD by inhibition of NLRP3 in order to reduce amyloid- β aggregation. Aimanianda et al. (TIPS, 30 (6) (2009): 287-295) discloses that alum activates NLRP3.

Magga et al. (J. Cell. Mol. Med. 16 (2012): 1060-1073) report the production of monocytic cells from bone marrow stem cells and their therapeutic use in AD. Lebson et al. (Cell Transp. Cogn. Com. 17 (2008): 470/471) disclose monocyte gene therapy in AD APP+PS1 transgenic mice. WO 2012/055981 A1 suggests the use of a "TLR4 agonist free of endotoxin" for the prevention or reduction of amyloid deposition. Malm et al. (GLIA 58 (2010): 889-900) review the role and therapeutic potential of monocytic cells in AD.

WO 2009/105641 A1 discloses the use of M-CSF for the treatment of amyloidosis. Boissionneault et al. (Brain 132 (4) (2008): 1078-1092) report the effects of M-CSF on amyloid deposition and cognitive impairment in AD. Luo et al. (Neuroscience letters 367 (2) (2013): 210-172) disclose that Colony-stimulating factor 1 receptor (CSF1R) signalling in injured neurons facilitates protection and survival.

Accordingly, so far no effective, disease modifying treatment is available to stop the progressive neurodegeneration and associated cognitive decline in human patients. Available treatment modalities for AD include three acetylcholinesterase inhibitors (AChEI) and one N-Methyl-D-aspartate (NMDA) antagonist. Their effects are small and only symptomatic in nature (see e.g. Corbett et al., Nat. Rev. Drug Discov. 11 (2012), 833-846). Thus, there is a high medical need for a disease-modifying drug.

It is an object of the present invention to provide means and methods for the treatment and prevention of AD enabling a cure to AD in the meaning that the status of the diseased patient is not further developing or even ameliorated. Another object is to provide means and methods for preventing the development of AD in persons having or being at risk of developing AD. More specifically, it is an object of the present invention to

provide efficient AD treatment, as proven with respect to at least one significant biomarker, as measured by brain imaging modalities using MRI (Magnetic resonance imaging) or emission tomography based techniques.

Therefore, the present invention provides a method for the treatment of AD wherein an immune stimulating pharmaceutical composition comprising an aluminium salt is administered to a patient having AD or having a risk to develop AD in an effective amount.

In the course of the present invention it has surprisingly turned out that aluminium salts as such have proven in clinical trials to be effective in providing real disease modifying effects in AD patients leading to clinical efficacy hitherto not seen in any of the clinical trials for AD medication so far. The present invention therefore provides a breakthrough technology for this disease. For the first time, a significant disease modifying effect could be detected in AD patients. Moreover, the present invention has also turned out to be effective without the significant side effects reported in other clinical trials for AD medication, especially in the field of AD immunotherapy.

More specifically, the present invention has achieved a statistically significant disease modifying effect in AD patients with respect to MRI scans of the volume of the (right) hippocampus. Moreover, for the first time, the correlation of a clinical biomarker and a radiologic biomarker has been shown in the course of clinical trials performed for the present invention. Structural MRI has been highlighted as a significant biomarker, in the most recent scientific literature (Risacher et al., *Annu. Rev. Clin. Psychol.* 9 (2013), 621-648; Vermuri et al., *Neurology* 73 (2009), 287-293 and 294-301; Weiner et al., *Alzh. Dememt.* 9 (2013), e111-94; Frisoni et al., *Nat. Rev. Neurol.* 6 (2010), 67-77; Fox et al., *Arch. Neurol.* 57 (2000), 339-344).

MRI provides great power to effect cross-sectional groupwise discrimination and better correlation with general cognition and functional status cross-sectionally. MRI reflects clinically defined disease stage even better than various CSF biomarkers tested (Vermuri et al., *Neurology* 73 (2009), 287-293 and 294-301). Numerous studies have demonstrated significantly reduced hippocampal and entorhinal cortex (EC) volume, as well as reduced cortical thickness in the medial and lateral temporal cor-

tex, parietal lobe, and frontal lobes, in patients destined to convert from MCI to probable AD (MCI-converters), up to two years prior to clinical conversion (Risacher et al., 2013).

Accordingly, this biomarker was investigated in the course of the clinical trials performed for the present invention in parallel with the standard clinical parameters (monitoring functional and cognitive function of AD patients).

With the present invention, a significant improvement in the development of AD patients compared to the usual development of AD patients (gradual cognitive, functional and behavioural decline) can be achieved so as to satisfy the long-felt need of providing a disease-modifying treatment of AD.

Accordingly, subject matter of the present invention is the use of an aluminium salt in the treatment and prevention of dementias associated with β -amyloid deposition, preferably AD, wherein an effective amount of such aluminium salt is administered to a patient suffering from the β -amyloid deposition or being at risk of developing a β -amyloid deposition, preferably a patient having or being at risk of developing AD, Dementia with Lewy bodies and Dementia in Down syndrome, especially AD.

Aluminium salts have a long-standing use as adjuvants in vaccines, however, during the years the pharmaceutical use of such salts has been reduced to mostly two suspension preparations, namely Alhydrogel (aluminium-oxyhydroxide) and AdjuPhos (aluminiumhydroxyphosphate), onto which antigens are adsorbed for vaccine preparations (reviewed in E. B. Lindblad (2004) Vaccine 22, 3658-3668; E. B. Lindblad (2004) Immunology and Cell Biology 82, 497-505; R. K. Gupta (1998) Adv. Drug Delivery Rev. 32, 155-172).

Despite its long use, the mode of action of Alhydrogel as an adjuvant is poorly understood. The initial hypothesis, that Alhydrogel forms a depot at the injection side has turned out to be only one part of a multi-faceted story (reviewed in C. Exley, P. Siesjö, H. Eriksson (2010) Trends Immunol. 31, 103-109; S. L. Hem, H. HogenEsch (2007) Expert Rev. Vaccines 6, 685-698; P. Marrack, A. S. McKee, M. W. Munks (2009) Nature Rev. Immunol. 9, 287-293; S. G. Reed, M. T. Orr, C. B. Fox (2013) Nat. Med. 19, 1597-1608).

The main presentations of aluminium adjuvants used in humans are aluminium hydroxide (or aluminium oxyhydroxide) and alumin-

um phosphate. Both presentations are usually prepared by exposing a soluble aluminium salt (historically potassium alum, i.e. $\text{KAl}(\text{SO}_4)_2 \cdot 12\text{H}_2\text{O}$, was often used) to alkaline conditions, upon which a suspension is formed. Characterisation with X-ray crystallography and IR spectroscopy revealed a boehmite-like structure (aluminium oxyhydroxide) for aluminium hydroxide and an amorphous structure corresponding to aluminium hydroxyphosphate for aluminium phosphate.

Therefore, preferred aluminium salts according to the present invention have the general formula $\text{Me}_a^+ \text{Al}_b^{3+} \text{An}^{c-} \cdot n\text{H}_2\text{O}$, wherein Me^+ is Na^+ , K^+ , Li^+ , Rb^+ , Cs^+ or NH_4^+ ; An is PO_4^{3-} , SO_4^{2-} , $\text{O}(\text{OH})^{3-}$, O_2^- or OH^- ; a is 0, 1, 2, or 3; b is 1 or 2; c is 1, 2, 3, 4, 5, or 6; and n is 0 to 48.

Preferred examples of such aluminium salts are those that have been studied, examined and verified in and for human use, such as aluminium hydroxide, aluminium oxyhydroxide, aluminium phosphate, aluminium sulphate, or any kind of "alum" (wherein "alum" is usually referred to a class of chemical compounds, including the "classical alum", a hydrated potassium aluminium sulfate (potassium alum) with the formula $\text{KAl}(\text{SO}_4)_2 \cdot 12\text{H}_2\text{O}$, and - more generally double sulfate salts, with the formula $\text{AAl}(\text{SO}_4)_2 \cdot 12\text{H}_2\text{O}$, where A is a monovalent cation such as potassium or ammonium).

The most preferred embodiments of the aluminium salts according to the present invention are selected from aluminium hydroxide, aluminium oxyhydroxide, aluminium phosphate, or aluminium sulphate, especially aluminium oxyhydroxide, which has been intensively investigated in the course of the present invention, since it is the preferred adjuvant in human use (as Alhydrogel adjuvant in various vaccines).

The aluminium salt according to the present invention may be admixed with other substances to achieve the disease-modifying effects according to the present invention. However, since the aluminium salts according to the present invention have also a protein binding capacity (also depending on the pI of the protein and the pH of the pharmaceutical preparation), the aluminum salt concentrations have to be increased when proteins or poly-

peptides are present in the pharmaceutical preparation to be administered to a patient.

For example, aluminium phosphate (Adju-Phos) has a maximal binding capacity (in mg protein/mg aluminum at pH 7.4) to Lysozyme (pI 11.0) of 1.4 ± 0.1 ; aluminium oxyhydroxide (Alhydrogel) to Ovalbumin (pI 4.6) of 1.6 ± 0.1 and to BSA (pI 4.9) of 2.2 ± 0.1 (Jones et al., JBC 280, (2005), 13406-13414). In order to account for the aluminium that is bound to such proteins, more aluminium salt has to be provided in such admixed pharmaceutical preparations than in preparations that contain the aluminium salt as the single effective ingredient or - at least in the absence of proteins or polypeptides in the pharmaceutical preparation. For example, if a pharmaceutical composition according to the present invention should provide the effectiveness of a dose of 2 mg aluminium salt, especially aluminium oxyhydroxide, and contains a specific amount of proteins or polypeptides which binds to the aluminium salt, an amount equal to the aluminium salt portion binding to such proteins has to be additionally included in the pharmaceutical preparation to provide 2 mg "free" aluminium salt.

It is therefore preferred to administer the aluminium salt according to the present invention contained in a pharmaceutical preparation, wherein this preparation contains the aluminium salt, especially aluminium oxyhydroxide, as the single effective ingredient.

The most preferred embodiment of the present invention comprises the effective administration of aluminium oxyhydroxide (particularly as Alhydrogel) to AD patients.

Aluminium oxyhydroxide preparations have a point of zero charge at a pH of \sim pH 11, while aluminium hydroxyphosphate might have a point of zero charge as low as pH 4 (depending on the phosphate content). Therefore aluminium oxyhydroxide and aluminium hydroxyphosphate have an opposite surface charge at neutral pH, with the latter being negatively charged. It has to be mentioned, however, that the surface charge may change depending on the exact buffer composition, especially phosphate ions have the capacity to lower the surface charge of aluminium oxyhydroxide.

For aluminium oxyhydroxide, the preparation is devoid of anions such as sulphates, nitrates, or chlorides and has a speci-

fied heavy metal content of less than 20 ppm. The suspension of aluminium oxyhydroxide has a particle size distribution between 2 μm and approximately 10 μm , which are aggregates composed of smaller fibers of $\sim 2\text{nm} \times 4.5 \text{ nm} \times 10\text{nm}$.

According to this most preferred embodiment, the current invention relates to the use of European Pharmacopoeial grade (Aluminium-oxyhydroxide, monograph 1664), more specifically to the product manufactured by Brenntag Biosector (2% Alhydrogel) tested towards EP compliance. Alhydrogel is available in three varieties: Alhydrogel 1.3%; Alhydrogel 2% and Alhydrogel "85". Alhydrogel 2% was elected as the International Standard Preparation for aluminium hydroxide gels. The pharmaceutical preparation according to the present invention is aseptically formulated into a suitable buffer, preferably an isotonic phosphate buffer (1mM to 100 mM), preferably at a concentration of $\geq 1.0 \text{ mg/ml}$ Alhydrogel (given as Al_2O_3 equivalent; this metric (Al as " Al_2O_3 equivalent") is used generally for the present invention; accordingly, all doses and amounts referred to in the present application, as far they are relating to aluminum salts (especially as far as they are relating to aluminium oxyhydroxide) refer to Al_2O_3 equivalents (of aluminium oxyhydroxide (Alhydrogel))), even more preferably at a concentration of $\geq 1.5 \text{ mg/ml}$ Alhydrogel (given as Al_2O_3 equivalent), most preferable at a concentration of $\geq 2.0 \text{ mg/ml}$ Alhydrogel (given as Al_2O_3 equivalent). The amount of aluminium salt for Alhydrogel is given as Al_2O_3 equivalent in line with the strength as stated by the manufacturer (i.e. 2% Alhydrogel equates to 2% Al_2O_3 , i.e. 20 mg/mL). This concentration is directly convertible into the respective concentration of aluminium by using the respective molecular masses (20 mg/mL Al_2O_3 (Mw 101,96) corresponds to 10.6 mg/mL aluminium (molecular mass 26,98)). Depending on the salt used this value can easily be converted into the necessary amount/concentration of a different aluminium salt (it is clear that these values are based solely on the amount of aluminium (salt), and other aspects, such as the contribution of the particulate nature of Alhydrogel is not taken into account.

Alhydrogel 2%, often also referred to as alum, is an aluminium oxyhydroxide wet gel suspension.

In the most preferred embodiment of the present invention, the aluminium salt to be administered to the AD patient is an

aluminium oxyhydroxide suspension, preferably European Pharmacopoeia grade aluminium-oxyhydroxide (monograph 1664), especially Alhydrogel. The aluminium oxyhydroxide is administered in an amount effective to achieve an AD ameliorating effect, as defined by the EMEA Guideline on medical products for the treatment of AD and other dementias (Document Ref. CPMP/EWP/553/95 Rev.1 of 24 July 2008). Accordingly, any administration procedure or dosage regimen for the aluminium salt formulation, especially aluminium-oxyhydroxide formulation, according to the present invention that is suitable to achieve the AD modifying effect as provided by the present invention is subject to the present invention. The term "effective amount" has also been defined as the amount of compound necessary to inhibit physiological effects or disorders associated with an amyloidogenic protein, or inhibit amyloidogenic production or deposition, or inhibit AD, as the case may be.

Although it is possible to deliver the preparation according to the present invention by way of slow infusion, the preferred strategy for administration is by administration of doses, for example by subcutaneous injection. Preferably, therefore the administration dose of the aluminium salt, preferably aluminium oxyhydroxide, is of at least 1.2 mg to an AD patient. A preferred range of amount to be administered to a patient is an amount of the aluminium salt, preferably aluminium oxyhydroxide, of 1.2 mg to 5.0 mg. The AD ameliorating effect of the aluminium salt, preferably aluminium oxyhydroxide, administration is even more pronounced at an amount of at least 1.5 mg. According to another preferred embodiment the aluminium salt, preferably aluminium oxyhydroxide, is administered in an amount of 1.5 mg to 5.0 mg, preferably 1.5 to 3.0 mg, especially 1.5 to 2.5 mg, to an AD patient. Another preferred embodiment comprises administration of the aluminium salt, preferably aluminium oxyhydroxide, in an amount of 1.6 mg to 2.5 mg, preferably 1.8 to 2.2 mg, especially 1.9 to 2.0 mg, to an AD patient.

According to another preferred embodiment, the aluminium salt, preferably aluminium oxyhydroxide, is administered in amount of 2.2 mg or higher. This amount is even higher as prescribed in the US general biological products standards (U.S.C. 21 CFR 610.15 (as of 1 April 2013)). Such preferred higher ranges of the aluminium salt, preferably aluminium oxyhydroxide, are

i.a. 2.2 to 10 mg, 2.2 to 8 mg, 2.2 to 5 mg, and 2.2 to 4 mg for one administration dose.

Preferably, the aluminium salt is the single effective substance to be applied in the administration dose. The aluminium salt preparation according to the present invention may, however, contain various auxiliary substances that have no specific clinical effect but are useful in the dosage form to be administered, be it for administration purposes, storage purposes, or other purposes. According to a preferred embodiment, the aluminium salt preparation, preferably the aluminium oxyhydroxide preparation, to be applied according to the present invention contains a pharmaceutically acceptable carrier, diluent or excipient, for example water for injection. Preferably, the aluminium salt preparation, especially the aluminium oxyhydroxide preparation, according to the present invention additionally contains one or more stabilisators, especially thiomersal, detergents, antioxidants, complexing agents for mono- or divalent metal ions, especially ethylenediaminetetraacetic acid (EDTA), sugars, sugar alcohols, glycerol, and/or buffer substances, especially TRIS or phosphate buffer substances. This, of course, also includes mixtures of such auxiliary substances.

The dosage form to be administered to the patients can be provided in any convenient volume, preferably as injectable suspension, e.g. with a volume of between 0.1 and 10 ml, more preferred of 0.2 to 5 ml, especially of 0.4 to 3 ml. Specifically preferred volumes are 0.5, 1, 1.5 and 2 ml. The pharmaceutical preparations according to the present invention are produced according to pharmaceutical Good Manufacturing Practice (GMP), as required and defined by the European and/or US Pharmacopeia.

According to a preferred embodiment, the aluminium salt, preferably the aluminium oxyhydroxide, is administered to a patient in a suspension with a pH of 4 to 10, preferably of 5 to 9, more preferred of 6 to 8, especially from 7.0 to 7.5. Preferably, the suspension is an isotonic suspension.

Preferably, the aluminium salt is administered by a route that is as convenient as possible for the AD patient but is still effective to achieve an AD modifying effect. Most effective treatment routes of the aluminium salt, preferably aluminium oxyhydroxide, according to the present invention are subcutaneous, intranodal, intradermal, or intramuscular administration,

especially subcutaneous administration. Subcutaneous administration is performed as a bolus into the subcutis, the layer of skin directly below the dermis and epidermis, especially in the fatty tissue in the subcutis.

Administration regimes can be optimised individually for each AD patient, depending on the treatment success, as measured by various parameters, especially by cognitive and functional performances and by biomarkers, especially structural MRI concerning hippocampus volume (see below). In the course of the clinical trials conducted for the present invention, at least monthly administrations of the aluminium salt, preferably aluminium oxyhydroxide, to an AD patient have proven to be successful in ameliorating AD. In order to achieve a long lasting therapeutical effect, such at least monthly administrations should be continued for at least three months, especially at least six months.

Administration of the aluminium salt, preferably aluminium oxyhydroxide, according to the present invention may also be performed at least twice a month (for example bi-weekly or weekly); also in such a dosage regimen, the aluminium salt, preferably aluminium oxyhydroxide, should be administered to an AD patient at least for a period of three months, preferably for at least six months, more preferred for at least twelve months, especially at least 24 months.

According to a preferred embodiment the aluminium salt, preferably aluminium oxyhydroxide, is administered to an AD patient subcutaneously in the (outer area of the) upper arm, preferably alternating in the left and in the right upper arm (i.e. administering the first dose into the right (or left) upper arm and the second dose into the left (right arm), and so on). Other convenient (or alternative) areas for subcutaneous administration are just above and below the waist (except the area right around the navel (a 2-inch circle)), the upper area of the buttock, preferably just behind the hip bone, the front of the thigh, midway to the outer side, 4 inches below the top of the thigh to 4 inches above the knee, etc..

Alternatively, the dose to be administered can also be split into two (or more) split doses that are administered simultaneously (at the same physician date; at least at the same day) to the AD patient. For example, a dose of 2 mg may be split to

split doses of 1.8 and 0.2 mg, 1.7 and 0.3 mg, 1.5 and 0.5 mg, 1.34 and 0.76 mg, 1.0 and 1.0 mg, 1.05 and 0.95 mg, 1.0, 0.5 and 0.5 mg, 0.6, 0.6 and 0.7 mg, 0.2, 0.5, and 1.3 mg, 0.5, 0.5, 0.5 and 0.5 mg, 0.2, 0.3, 0.5 and 1.0 mg, etc.. The split doses may be administered at different administration sites or, preferably, at the same site of administration. The "same site of administration" is within an area of 10 cm² of the skin, preferably within an area of 5 cm² of the skin, especially within 1 cm² of the skin. Preferred split doses contain the aluminium salt, preferably aluminium oxyhydroxide, in an amount of 0.8 to 5.0 mg, preferably of 1.0 to 3.0, especially from 1.0 to 1.5 mg.

In order to achieve a very long lasting effect of the AD amelioration, the treatment according to the present invention is performed for longer than one year. According to a preferred embodiment of the present invention, the aluminium salt is administered at least monthly for at least two years, preferably at least four years, especially at least 8 years, to an AD patient.

Administration of the aluminium salt, preferably the aluminium oxyhydroxide, according to the present invention may be performed by any suitable administration device. For convenience reasons, the aluminium salt dose, preferably the aluminium oxyhydroxide dose, is administered by an injection device, especially a syringe, to an AD patient. The pharmaceutical preparations for use in the present invention can be provided in any suitable form. Preferably, they are provided in a storage stable form. Storage stability can be assured by various means, such as sterilisation, addition of stabilisers, freezing, lyophilisation, etc. Preferably, combinations of such means are used to enhance storage stabilities of such preparations. When aluminium salt agents, such as aluminium oxyhydroxide are frozen or lyophilized, an aggregation of adjuvant particles during processing may be observed. By cooling such formulations, especially aluminium oxyhydroxide (Alhydrogel) formulations, at faster rates or by the addition of sufficient amounts of a glass forming excipient, such as trehalose, aggregation of Alhydrogel, can be prevented or minimized. It was proposed that freeze-concentration of buffer salts induces modifications in surface chemistry and crystallinity of such aluminium agents, which in turn favour aggregation. These modifications and the resulting

aggregation of such Alhydrogel particles can be excluded or minimized through choice of buffer ions, or kinetically inhibited by rapidly forming a glassy state during freezing (see e.g. Clausi et al., J Pharm Sci. 2008 Jun;97(6):2049-61).

The pharmaceutical compositions to be applied to AD patients according to the present invention are manufactured (and finished) into suitable containers, and sold for example in sealed vials, ampoules, cartridges, flexible bags (often constructed with multi-layered plastic), glass or polypropylene bottles or, preferably, in syringes, especially in prefilled (ready-to-use or ready-to-reconstitute) syringes.

According to a preferred embodiment of the present invention, the aluminium salt, preferably the aluminium oxyhydroxide, is administered in an amount of at least 1.8 mg to an AD patient.

Preferred patients to which the aluminium salt preparations, preferably aluminium oxyhydroxide preparations, according to the present invention is administered are AD patients that are early stage patients, including those patients that are often also referred to as "patients with mild cognitive impairment" (MCI). The concept of MCI was developed in the 1990s to capture patients with early clinical signs of Alzheimer disease (AD) who did not yet fulfil the criteria for dementia. The amnesic variant of MCI features the following: memory complaints, preferably qualified by an informant; memory impairment for age, as indexed by low cognitive performance in one or more neuropsychological tests that tap into learning abilities (for example, prose recall, word list); preserved general cognitive function (for example, Mini-Mental State Examination score of 24 out of 30 or above); intact activities of daily living; and no dementia. About two-thirds of all patients with amnesic MCI harbour the pathological features of AD and develop the clinical syndrome of Alzheimer dementia within 5 years, whereas the remaining one-third have non-progressive or very slowly progressive causes of cognitive impairment (for example, depression or age-related cognitive impairment). Proposed new diagnostic criteria for AD developed in 2007 (Dubois et al., Lancet Neurol. 6 (2007), 734-746) suggested that the disease can be recognized at the MCI stage if the patient is positive for at least one of the following four markers: medial temporal atrophy on MRI; temporopari-

tal cortical hypometabolism on 18F-fluorodeoxyglucose PET; abnormality of cerebrospinal fluid markers (tau, amyloid- β 42 or phospho-tau); and positivity on amyloid imaging with PET. This patient population is not only included in the AD patients to be treated according to the present invention, it is a specifically preferred group of patients for which the treatment method according to the present invention is specifically effective. This is in line with the revised criteria for AD clinical trials adopted by the US-FDA (Aisen et al., 2013; Kozauer et al., 2013). Accordingly, it is preferred to treat patients in an early state of AD, as defined by a relatively high MMSE (minimal state examination or Folstein test) score. Preferably the AD patient to be treated according to the present invention is a patient with an MMSE score of between 23 and 30 (30 being the maximum), preferably between 24 and 30, more preferably between 25 and 29, especially between 26 and 29. Other preferred patient groups are patients greater than or equal to 27 points (indicating a normal cognition), 25 to 27 (slightly below normal cognition) or 19 to 24 (mild points cognitive impairment).

Early stage AD patients can also be selected by other scores, preferably scores that combine cognitive and functional parameters (and numerical limits) for limiting AD population to be (effectively treated), such as ADAS-cog, etc.

The present invention provides for the first time an AD treatment that is disease modifying. The effectiveness of the treatment according to the present invention is proven by the parameters required by the drug authorisation authorities, especially the EMEA and the US-FDA. For example, the EMEA guideline for AD treatment requires primary endpoints reflecting the cognitive and the functional domain. Accordingly, a combined (Composite) score is used for the clinical assessment of the present invention. This composite score combines two established scores, one for the cognitive function (ADAS-cog (Alzheimer's Disease Assessment Scale-cognitive subscale)) and one for the functional ability (ADCS-ADL (Alzheimer's Disease Co-operative Study - Activities of Daily Living Inventory)). The adapted ADAS-cog combines items that assess cognitive function. The adapted ADCS-ADL includes items that are sensitive to functional ability. Cognitive skills are expected to decline toward the beginning of the disease and one's ability to perform basic functions are ex-

pected to decline later in the disease. The combined primary outcome (Composite score according to the present invention) combines both the adapted ADAS-cog and adapted ADCS-ADL to create a composite that is sensitive to decline in cognitive and basic functions. The following equation is used to derive the combined primary outcome, i.e. combined composite:

Combined composite according to the present invention:
$$= 1.67 * \text{Word recall} + 1.35 * \text{Orientation} + 1.42 * \text{Word Recognition} + 0.55 * \text{Recall Instructions} + 0.81 * \text{Spoken Language} + 1.01 * \text{Word Finding} + 5.42 * \text{ONB} + 0.15 * \text{VPAL} + 0.19 * \text{Category Fluency} + 0.28 * \text{Belongings} + 0.35 * \text{Shopping} + 0.23 * \text{Hobbies} + 0.38 * \text{Beverage} + 0.37 * \text{Meal} + 0.23 * \text{Current Events} + 0.26 * \text{TV} + 0.33 * \text{Keeping Appointments} + 0.37 * \text{Travel} + 0.33 * \text{Alone} + 0.35 * \text{Appliance} + 0.49 * \text{Clothes} + 0.36 * \text{Read} + 0.62 * \text{Telephone} + 0.33 * \text{Writing}$$

Furthermore, AD biomarkers were observed with the present invention that are characteristic for AD development. EMEA and FDA criteria recommend newer techniques, such as MRI, especially atrophy of entorhinal or (para-) hippocampal cortex. With the present invention, PET (Positron emission tomography)-MRI was applied. More specifically, volume of right hippocampus (important for learning and memory of material that is difficult to verbalise) is used according to the present invention as significant AD biomarker for treatment success.

According to the present invention, a clinical effect in AD treatment can be observed which can be measured by a reduction in cognitive and/or functional decline (over a treatment period of about one year) by at least 30 % (calculated by the score decline), preferably by at least 50 %, especially by at least 70 %, compared to a normal development of decline in AD patients. Preferably, cognitive and functional parameters remain essentially unchanged during treatment. This can be achieved by the present invention especially in patients with earliest stage patients (as suggested and recommended by the guidelines of EMEA and FDA), for example AD patients with MMSE of 23 or higher, preferably of 24 or higher, more preferred of 25 or higher, especially of 26 or higher. For those patients, Composite score change during treatment according to the present invention was still around the initial score after 18 months. This is significantly more than the minimum requirements for "disease modifying effects" as required by the EMEA ("From a regulatory point of

view, a medicinal product can be considered as disease modifying, if the progression of the disease as measured by cognitive and functional assessment tools is reduced or slowed down and if these results are linked to an effect on the underlying disease process"; "a disease modifying effect will be considered when the pharmacologic treatment delays the underlying pathological or pathophysiological disease processes and when this is accompanied by an improvement of clinical signs and symptoms of the dementing condition").

The invention is further explained by way of the following examples and the figures, yet without being limited thereto.

Fig. 1 shows the results of the clinical trial according to the present invention with respect to the change in Composite score composed of (partial) Adapted ADL change and Adapted ADAS-cog change for all patients who have received the 2 mg and 1 mg aluminium oxyhydroxide treatment.

Fig. 2 shows a comparison of the mild population of patients (the mild population is defined by a baseline MMSE score of 24 and higher) of both groups showed that this effect is most pronounced in the cohort of patients in earlier disease stages.

Fig. 3 shows slowing of disease progression apparent in the 2 mg and 1 mg aluminium group as evidenced by Adapted ADAS-cog (ADAS-cog items only; Least Squares Means) for the 1 mg and 2 mg aluminium oxyhydroxide group compared to the historical control (p-values: 1 mg vs. HC-ADNI,NS,HC: <0.0001; 2 mg vs. HC-ADNI,NS,HC: <0.0001).

Fig. 4 shows development of volume (in mm³) of right hippocampus for 2 mg and 1 mg aluminium oxyhydroxide treatment group of the mild population of patients (the mild population is defined by a baseline MMSE score of 24 and higher), showing that this effect is most pronounced in the cohort of patients in earlier disease stages.

Fig. 5 shows the Quality of Life-Alzheimer's disease (QOL-AD) for caregivers. Caregivers completed the measure as a questionnaire about their patients' QOL. The measure consisted of 13 items, rated on a 4 point scale, with 1 being poor and 4 being excellent. Outcomes are shown as the change over time using a least squares means from a mixed model.

Fig. 6 shows immune response of the mice tested in the Tg2576 animal model: Tg2576-mice were injected 6x, s.c., at 4-

week intervals with either conjugate-vaccine containing 30µg net peptide, KLH formulated with Alum or Alum only. Alum doses used were equivalent to 2mg/ml. Vaccination induced Abs were measured in plasma samples taken at sacrifice (SeqID 1 (n=10), SeqID 2 (n=8), KLH-Alum (n=10) and Alum only (n=8)). Samples were analyzed for their concentration of IgG Abs against specific peptides. Values depicted are the titer calculated as OD max/2 (at 405nm) plus SEM. IgG response towards the respective immunizing peptide (SeqID 1: anti SeqID 1; SeqID 2: anti SeqID 2, KLH-Alum: anti KLH, Alum: anti AD02); B) Reactivity towards human Aβ1-40/42 after immunization. SeqID 1 (n=10) and SeqID 2 (n=8), treated animals show anti Aβ40/42 reactivity, KLH-Alum and Alum only treated animals do not show reactivity above background. Background for this assay was set to 1/100, indicated by black lines and an asterisk in A+B.

Fig. 7 shows memory and learning of the mice tested: Groups of Tg2576 mice (n≤10/group) received 6 monthly injections of KLH/ALUM (n=9) or SeqID 1-KLH-Alum (n=10)-, SeqID 2-KLH-Alum (n=7) -conjugate vaccines or ALUM only (n=8). Naïve wt animals (n=20) were used as positive controls for Contextual fear conditioning (CFC). Contextual learning and memory was assessed by CFC-analysis using % of time freezing at the end of CFC testing. Parameter depicted is the % of time the animals are 99% immobile during a representative 2-minute period on day two of the CFC testing paradigm. *..p<0.05; **..p<0.01.

Fig. 8 shows amyloid load in the animals tested: Groups of Tg2576 mice (n≤10/group) received 6 monthly injections of KLH/ALUM (n=9) or SeqID 1 (n=10)-, SeqID 2 (n=7)-conjugate vaccines or ALUM only (n=8). Alum dose in all formulations equivalent to 2mg/ml. Brains were isolated, 8 weeks after the 6th immunization. Quantification of the relative total brain area covered by amyloid deposits (in % of total tissue analyzed) is based on immuno-fluorescence staining using the Aβ specific mAb 3A5. Representative subregions of the cortex (A, B) and dentate gyrus (C, D) of controls (A, C) and SeqID 1- (B, D) immunized mice are shown. E) SeqID 1-KLH Alum + SeqID 2-KLH Alum reduces the relative area covered by amyloid deposits compared to KLH-Alum controls significantly (diffuse and dense cored amyloid; *..p<0.05, **..p<0.01). A slight but insignificant reduction in

A β deposition is detectable in Alum only treated vs. KLH-Alum treated animals. (ns) Arrowhead in C indicates unspecific fluorescence from a cerebral vessel. Scale bar: 200 μ m; pictures taken at 10x magnification.

EXAMPLES:

1. Excerpt of an AD clinical trial (AFF006; Eudract: 2009-016504-22)

Materials and Methods:

Data supporting the invention are derived from a randomized clinical trial in early AD patients. The study (AFF006; Eudract: 2009-016504-22) randomized early AD patients into 5 treatment arms. Patients of 2 study arms received either 1 mg aluminium or 2 mg aluminium. In total, 99 early AD patients were enrolled into the 2 study arms. Participation of a given patient lasted 18 months.

Study design:

AFF006 was conducted as a randomized, placebo-controlled, parallel group, double-blind, multi-center phase II study and assessed the clinical and immunological activity as well as the safety and tolerability of repeated s.c. administrations of i.a. aluminium (different doses) in patients with early AD, as defined in the protocol. It was performed in a total of 6 countries: Austria, France, Germany, Slovakia, Czech Republic and Croatia.

The clinical trial comprised 10 regular outpatient visits and 6 telephone interviews. Up to four weeks before start of treatment, a screening visit (Visit 1) was performed to ensure suitability of the patients for the clinical trial and to establish the patients' baseline characteristics. Following screening, eligible patients were randomly allocated to the treatment groups. After randomization at week 0, patients received 6 injections with either 1 or 2 mg aluminium. Injections were applied s.c. by the investigator at weeks 0, 4, 8, 12, 40 and 65 (Visit 2, 3, 4, 5, 7 and 9).

At Visits 2, 3, 4, 5, 6, 7 and 9 possible local and systemic reactions to the vaccine and vital signs (blood pressure, heart

rate, respiratory rate and body temperature) were assessed. In addition, a physical and neurological examination was performed. Efficacy parameters were assessed at Visits 1, 2, 3, 5, 6, 7, 8, 9, 10. The final visit (Visit 10) was performed twelve weeks after the last administration of study drug (Visit 9). An early discontinuation visit (EDV) was performed when a patient discontinued from the clinical trial.

Study population

The study was done in patients with early AD. Diagnosis was defined by the following criteria:

- probable Alzheimer's disease as defined by NINCDS/ADRDA criteria (1)
- MMSE score ≥ 20 (2)
- result of Free and Cued Selective Reminding Test (FCSRT) result of total recall ≤ 40 or free recall ≤ 17 , indicating hippocampal damage impairing the patient's episodic memory (3)
- the result of a centrally read MRI of a patient's brain must be compatible with the diagnosis AD, in particular, presence of a medial temporal lobe atrophy (Scheltens Score ≥ 2) (4)

Other in-/exclusion criteria applied (e.g., written informed consent; age between 50 and 80 years, treatment with immunosuppressive drugs (exclusion)).

Administration of study drug

During the study Visits 2, 3, 4, 5, 7 and 9 the patient received study drug by the investigator, in total: six injections over a 65-week treatment period. Injections were applied to the external surface of the upper arm, approximately 8-10 cm above the elbow. Prerequisite regarding the actual site was the presence of an intact regional lymph node station. If the draining lymph node stations of both upper arms were not intact, injection was placed into the thigh close to the inguinal lymph nodes. Two alternating injection sites (e.g. left and right upper arm, left upper arm and left thigh) were used throughout the 6 injections.

Injections were applied to the subcutaneous tissue (s.c.). Special care was taken to avoid intravascular application by care-

ful aspiration before each injection. All administrations were performed at the trial site.

Volume-based morphometry

Hippocampus (left and right), and whole lateral ventricle ROIs were delineated on an anatomical MRI template in order to generate the atlas for volumetric measures. The volumes of the hippocampus and lateral ventricles for each subject were determined using a fully-automated method which combines transformations derived from the nonlinear registration of the atlas labels to individual subject scans and subject-specific image information (Collins et al., J. Comput. Assist. Tomogr., 18: 192-205, 1994). Lateral ventricle and hippocampal segmentations that failed post-processing QC review were manually corrected. The total intracranial volume (TIV) was estimated from the brain mask generated during pre-processing and the average TIV (TIV_{avg}) for each subject was determined by averaging the estimated TIV across visits. The normalization factor ($TIV_{template}/TIV_{avg_subject}$) was used to normalize the hippocampal and ventricular volumes for each subject in order to account for differences in head size.

Safety assessments:

Safety evaluations included the following:

- adverse events (AEs) and serious adverse events (SAEs) (number of patients who withdrew due to AEs; reason for withdrawal)
- Laboratory assessments: hematology, biochemistry, coagulation, serology, urinalysis, APP crossreactivity
- vital signs (blood pressure, heart rate, respiratory rate and body temperature)
- physical and neurological examination

Efficacy assessments:

The primary efficacy variables are the change from baseline (CFB) in cognition as measured by an adapted ADAS-cog, CFB in function as measured by an adapted ADCS-ADL and a combination of CFB in cognition and function as measured by a combined composite:

1. Co-Primary: Adapted ADAS-cog;
2. Co-Primary: Adapted ADCS-ADL;

3. Combined Primary Outcome: Composite score.

ADAS-cog and other items included in the adapted ADAS-cog were measured at Visits 1, 2, 3, 5, 6, 7, 8, 9 and 10 or EDV. ADCS-ADL were measured at Visits 2, 5, 6, 7, 8, 9 and 10 or EDV. Items that contributing to the combined primary outcome were measured at Visits 2, 5, 6, 7, 8, 9 and 10 or EDV.

The primary efficacy outcomes all range from 0 to 100. For each adapted scale and composite, a lower score indicates better performance. However, some items included in a scale may be opposite in direction, i.e. a higher score indicates better performance. Before a composite was calculated, contributing items that are scored in the opposite direction were reversed. An item is reversed in score by subtracting the observed value from the maximum possible value for the item. This reverses the scale of the items so that a lower score now indicates better performance. The following items included in the adapted ADAS-cog and combined composite require reverse scoring: Verbal PAL, NTB Category Fluency and CogState ONB.

Secondary Efficacy Outcomes:

Quality of Life (QOL) caregiver

QOL caregiver is a brief, 13-item questionnaire designed to specifically obtain a rating of the QOL of the patient from the caregiver's perspective. Questions cover relationships with friends and family, concerns about finances, physical condition, mood, and an overall assessment of life quality. All items are rated on a four-point scale, with 1 being poor and 4 being excellent. The total score is the sum of all items, which can range from 13 to 52. QOL caregiver values are presented here as the change from baseline. Outcomes were measured at Visits 1, 6, 8, and 10.

Statistical analysis

Baseline data

Subjects were described using demographic information and baseline characteristics recorded during the screening phase (Visit 1).

Demographic information assessed was age, gender, racial

group, smoking habits, level of education, height and weight. Subject demographics was summarized by treatment for the Safety, ITT and Per Protocol populations.

Primary efficacy analysis

The primary, secondary and exploratory efficacy outcomes were analyzed by comparing change over time between the groups. The efficacy analyses utilized the mixed model described below. The mixed model analysis compared the estimated change from baseline between the 3 vaccine and the 2 aluminium groups in all efficacy outcome scores at each visit. The model used separate repeated measures longitudinal models for each efficacy end-point. This analysis assessed whether or not there is a difference in estimated CFB values between treatment groups.

SAS® PROC MIXED was used to fit a mixed model with repeated measures (MMRM), with CFB of each of the efficacy outcomes (e.g., Adapted ADAS-cog) as the response variable and the following covariates and fixed effects:

- ☐ Age (covariate);
- ☐ Level of Education (fixed effect split into categories of ≤ 12 years, > 12 years);
- ☐ Gender (fixed effect);
- ☐ Baseline Test Score of Efficacy Parameter (covariate);
- ☐ Center (fixed effect);
- ☐ Treatment (fixed effect);
- ☐ APOEε4 status (fixed effect, positive or negative);
- ☐ Use of AChE Inhibitors (fixed effect, determined from medications);
- ☐ Time (covariate, time will be defined in terms of visits);
- ☐ Time by Treatment Interaction (Time*Treatment);

The covariance structure for the model was first-order heterogeneous autoregressive (ARH[1]). Least-squares means were estimated at each visit in the study. The LS mean at a particular visit was interpreted as the expected CFB in the efficacy outcome at that time point (Visit) when the specified treatment was administered. Least squares means and standard errors were estimated from the mixed model at each visit and are shown for the various groups.

The adapted ADAS-cog combines items that assess cognitive

function. The adapted ADCS-ADL includes items that are sensitive to functional ability. Cognitive skills are expected to decline toward the beginning of the disease and one's ability to perform basic functions are expected to decline later in the disease. The combined primary outcome (referred to herein as "Composite score") combines both the adapted ADAS-cog and adapted ADCS-ADL to create a Composite score that is sensitive to decline in cognitive and basic functions. The following equation is used to derive the combined primary outcome, i.e. combined Composite score:

Combined Composite score:

$$= 1.67 * \text{Word recall} + 1.35 * \text{Orientation} + 1.42 * \text{Word Recognition} + 0.55 * \text{Recall Instructions} + 0.81 * \text{Spoken Language} + 1.01 * \text{Word Finding} + 5.42 * \text{ONB} + 0.15 * \text{VPAL} + 0.19 * \text{Category Fluency} + 0.28 * \text{Belongings} + 0.35 * \text{Shopping} + 0.23 * \text{Hobbies} + 0.38 * \text{Beverage} + 0.37 * \text{Meal} + 0.23 * \text{Current Events} + 0.26 * \text{TV} + 0.33 * \text{Keeping Appointments} + 0.37 * \text{Travel} + 0.33 * \text{Alone} + 0.35 * \text{Appliance} + 0.49 * \text{Clothes} + 0.36 * \text{Read} + 0.62 * \text{Telephone} + 0.33 * \text{Writing}$$

The percent contribution of each item to the combined Composite score can be found in Table 1 below:

Item	Percent Contribution
ADAS-cog Word Recall	16.6
ADAS-cog Orientation	10.8
ADAS-cog Word Recognition	17.0
ADAS-cog Recall Instructions	2.8
ADAS-cog Spoken Language	4.1
ADAS-cog Word Finding	5.1
CogState One-Back Memory	8.5
NTB VPAL	8.5
NTB Category Fluency	8.5
ADCS-ADL Belongings	0.8
ADCS-ADL Shopping	1.4
ADCS-ADL Hobbies	0.7
ADCS-ADL Beverage	1.1
ADCS-ADL Meal	1.5
ADCS-ADL Current Events	0.7

ADCS-ADL TV	0.8
ADCS-ADL Keeping Appointments	1.0
ADCS-ADL Travel	1.5
ADCS-ADL Alone	1.0
ADCS-ADL Appliance	1.4
ADCS-ADL Clothes	1.5
ADCS-ADL Read	0.7
ADCS-ADL Telephone	3.1
ADCS-ADL Writing	1.0

Results

AFF006 recruited a study population reminiscent of early AD patients based on demographic data (Table 2) and data showing the baseline characteristics of the study groups (Table 3).

Both the frequency and the intensity of the local reactions depend on the aluminium dose administered (Table 4). Such local reactions (LR) serve as a measure of the activation of the innate immune response.

2 mg aluminium group compares favourably even to the 1 mg aluminium group (other groups) with regard to parameters informing on the progression of the disease (Fig. 1). Comparison of the mild population of patients of both groups showed that this effect is most pronounced in the cohort of patients in earlier disease stages (Fig. 2). Slowing of disease progression over 18 months is specifically apparent in the 2 mg aluminium group, exemplified with Adapted ADAS-cog (Fig. 3).

Results obtained were compared to public datasets. Historical datasets identified were the ADNI 1 mild AD cohort (observational study), the mild placebo patients from the ADCS Homocysteine trial (HC, MMSE \geq 20) and the placebo group from the ADCS NSAID study of Rofecoxib and Naproxen (NS, MMSE \geq 20). These 3 cohorts were combined to yield the historical control (HC-ADNI,NS;HC). Data points were available for 344 patients at month 6, 317 patients at month 12 and 226 patients at month 18. The ADNI trial only performed assessments at 6, 12 and 24 months, so the 18 month value was imputed with a straight line. The NS study was only 12 months long, so no 18 month data was available from this study.

Although the adapted ADAS-cog used some items from the ADAS-cog supplemented with items from the NTB and the CogState Bat-

tery, these items were not available for all of the historical studies. So, an adapted ADAS-cog 2 was created which used the same weightings as the adapted ADAS-cog for the ADAS-cog items, but did not include the NTB and CogState items ($1.67 \times \text{Word recall} + 1.35 \times \text{Orientation} + 1.42 \times \text{Word Recognition} + 0.55 \times \text{Recall Instructions} + 0.81 \times \text{Spoken Language} + 1.01 \times \text{Word Finding}$).

The adapted ADAS-cog2 shows substantially more decline in the historical control group than the 1 and 2 mg aluminium oxyhydroxide treated groups from the AFF006 study (Figure 3). The p-values were: 1 mg vs. HC-ADNI, NS, HC: <0.0001 ; 2 mg vs. HC-ADNI, NS, HC: <0.0001 .

Also the MRI data show a statistically significant disease modifying effect for the 2 mg group of patients and a correlation of the hippocampus volume with clinical endpoints, e.g. right hippocampus with adapADAS: $p=0.0006$ or Composite score: $p=0.0095$) (Fig. 4). It has to be specifically mentioned that the present investigation has provided for the first time a parallel development of clinical data with a radiologic biomarker (MRI in the present case)).

Fig. 4 shows that the patients treated according to the present invention showed almost no AD related reduction in hippocampus volume over a period of 18 months whereas the rate of brain atrophy per year in AD patients is in the range of 3 to 6 % per year (Risacher et al., 2013, Table 2; the rate in healthy elderly individuals is usually in the range of 0.5 to 2.2 (see also this table 2 in Risacher et al.)).

Fig. 5 shows that caregivers of patients treated according to the present invention rated the QOL of the patient as significantly improved over a period of 18 months following 2mg compared to 1mg Alum and other groups (not shown).

Table 2: Patient Population and Disposition

Patient Disposition	1mg	2mg
	(N=48)	(N=51)
Number of Subjects n (%)		
Completed	41 (85.4%)	45 (88.2%)

Discontinued	7 (14.6%)	6 (11.8%)
P-value ¹		
Reason for Discontinuation from the Study:		
Death	2 (4.2%)	0 (0.0%)
Adverse Event	0 (0.0%)	0 (0.0%)
Withdrawal by Subject	4 (8.3%)	5 (9.8%)
Lost to Follow-up	0 (0.0%)	0 (0.0%)
Other	1 (2.1%)	1 (2.0%)

Table 3: Demographics - Race, Gender, Education, Age

Demographics	1mg	2mg
	(N=48)	(N=51)
Race		
Asian / Pacific Islander	0 (0.0%)	1 (2.0%)
Caucasian	48 (100.0%)	50 (98.0%)
Gender		
Male	28 (58.3%)	19 (37.3%)
Female	20 (41.7%)	32 (62.7%)
P-value ¹		
Education Years		
Mean (SD)	12.3 (4.03)	11.8 (3.18)
Median	12	11
(Q1, Q3)	(9.0, 15.0)	(10.0, 13.0)
Min, Max	8, 26	6, 22
P-value ¹		
Age (yrs)		
n	48	51
Mean (SD)	70.3 (6.56)	68.9 (8.36)
Median	71	69
(Q1, Q3)	(65.0, 75.5)	(64.0, 77.0)
Min, Max	57, 80	50, 80
P-value ¹		

Weight (kg)		
n	48	51
Mean (SD)	70.45 (10.375)	67.62 (13.700)
Median	70.5	65
(Q1, Q3)	(64.00, 77.70)	(57.00, 78.00)
Min, Max	47.5, 101.0	45.0, 100.0
P-value ¹		
BMI (kg/m ²)		
n	48	51
Mean (SD)	24.66 (2.903)	24.81 (3.627)
Median	24.8	24.2
(Q1, Q3)	(22.95, 26.15)	(22.30, 27.30)
Min, Max	17.8, 31.2	18.2, 35.4
P-value ¹		

Table 4: Adverse Event Summary of Local Reactions

MedDRA System Organ Class	1mg	2mg
Preferred Term		
	(N=48)	(N=51)
Number of subjects with reported adverse event	31 (64.6%)	42 (82.4%)
Number of unique events	96	162
General Disorders and Administration Site Conditions	31 (64.6%), 209	42 (82.4%), 487
Injection Site Erythema	26 (54.2%), 64	37 (72.5%), 143
Injection Site Swelling	13 (27.1%), 27	26 (51.0%), 86
Injection Site Warmth	18 (37.5%), 31	25 (49.0%), 67
Injection Site Induration	13 (27.1%), 32	14 (27.5%), 34
Injection Site Pain	14 (29.2%), 41	31 (60.8%), 99
Injection Site Pruritus	4 (8.3%), 5	10 (19.6%), 17
Injection Site Nodule	4 (8.3%), 5	11 (21.6%), 31
Injection Site Hypersensitivity	2 (4.2%), 2	4 (7.8%), 9
Injection Site Haematoma	2 (4.2%), 2	1 (2.0%), 1
Injection Site Discolouration	0 (0.0%), 0	0 (0.0%), 0

Injection Site Inflammation	0 (0.0%), 0	0 (0.0%), 0
Injection Site Reaction	0 (0.0%), 0	0 (0.0%), 0
Fatigue	0 (0.0%), 0	0 (0.0%), 0
Feeling Hot	0 (0.0%), 0	0 (0.0%), 0
Hypothermia	0 (0.0%), 0	0 (0.0%), 0
Injection Site Urticaria	0 (0.0%), 0	0 (0.0%), 0
Pyrexia	0 (0.0%), 0	0 (0.0%), 0
Investigations: Lymph Node Palpable	0 (0.0%), 0	0 (0.0%), 0
Investigations: Body Temperature Increased	0 (0.0%), 0	0 (0.0%), 0
Blood and Lymphatic System Disorders: Lymphadenopathy	0 (0.0%), 0	1 (2.0%), 1
Gastrointestinal Disorders: Glossitis	0 (0.0%), 0	1 (2.0%), 1
Gastrointestinal Disorders: Nausea	0 (0.0%), 0	0 (0.0%), 0
Gastrointestinal Disorders: Vomiting	0 (0.0%), 0	0 (0.0%), 0
Nervous System Disorders: Paraesthesia	0 (0.0%), 0	0 (0.0%), 0
Nervous System Disorders: Dizziness	0 (0.0%), 0	0 (0.0%), 0
Cardiac Disorders: Cyanosis	0 (0.0%), 0	0 (0.0%), 0
Infections and Infestations: Rash Pustular	0 (0.0%), 0	0 (0.0%), 0
Musculoskeletal and Connective Tissue Disorders: Pain in Extremity	0 (0.0%), 0	1 (2.0%), 1
Psychiatric Disorders: Tension	0 (0.0%), 0	0 (0.0%), 0
Vascular Disorders: Haematoma	0 (0.0%), 0	0 (0.0%), 0

2. Immunogenicity of two A β targeting vaccines SeqID 1-KLH-Alum and SeqID 2-KLH Alum in comparison to KLH-Alum and Alum only

SeqIDs:

SeqID 1: SWEFRTC

SeqID 2: SEFKHGC

Animal experiments:

All animal experiments were performed in accordance with the Austrian Animal Experiments Act (TVG2012) using Tg2576-mice (Taconic Farms, USA; 129S6/SvEvTac). General health was checked by modified Smith Kline Beecham, Harwell, Imperial College, Royal London Hospital, phenotype assessment (SHIRPA) primary observational screen (Rogers DC et al. (1999) Behav Brain Res 105: 207-217.). Mice were injected s.c. 6 times in monthly intervals. Blood was taken in regular intervals, plasma prepared and stored until further use. At study end mice were sacrificed, brains were collected and hemispheres separated. One hemisphere was fixed in 4% Paraformaldehyde (PFA, Sigma Aldrich, USA), dehydrated and paraffin-embedded. Brain tissue was sectioned at 7 μ m using a sliding microtome (Leitz, Germany) and sections were mounted on Superfrost Plus Slides (Menzel, Germany).

Titer determination by ELISA:

Standard enzyme-linked immunosorbent assay (ELISA) technology was used to measure levels of vaccine-induced antibodies in plasma and CSF (Mandler M et al. (2012) J Alzheimers Dis 28: 783-794.). Substrates used include human (BACHEM, CH) A β 1-40/42 (at 5 μ g/ml), KLH (1 μ g/ml) and peptide-Bovine serum albumin (BSA) conjugates (SeqID 1 and SeqID 2, 1 μ M). Optical density (OD) was measured at 405nm using a micro-well reader (Tecan, CH). OD_{max}/2 was calculated.

Behavioral tests:

To analyse cognitive dysfunction, immunised Tg2576 animals were subjected to contextual fear conditioning (CFC, Comery TA et al. (2005) J Neurosci 25: 8898-8902.), analyzed using AnyMaze software (Stoelting Co, USA). For CFC, on day 1 mice were placed in the conditioning chamber (AFFiRiS AG, Austria), allowed to habituate for 2 min. and received three 0.8mA foot-shocks in 2 min intervals plus 30s rest. To assess contextual learning on day 2, animals were readmitted to the chamber and monitored for 5 min. with s120-240 chosen as time frame for analysis (time freezing = lack of movement except for respiration). The first two minutes of day 1 were considered as baseline-freezing which was subtracted from day 2 values.

Analysis of cerebral A β :

Immunofluorescence (IF) analysis was done as described previously (Mandler M et al. (2012) J Alzheimers Dis 28: 783-794). For A β -specific IF-staining, brain sections of immunized Tg2576 were processed for analysis of amyloid load using mAb 3A5 (AF-FiRiS AG, Austria). All secondary reagents used were obtained from Vector Labs (USA). For IF, sections were mounted and counterstained using DAPI-containing VECTASHIELD-HardSet Mounting Medium. Sections were examined using MIRAX-SCAN (Carl Zeiss AG, Germany). AD-like pathology in animals was assessed by determining the relative cerebral area occupied by amyloid deposits using a semi-automated area recognition program (eDefiniens Architect XD; www.definiens.com, Mandler M. et al (2015) PLoS ONE 10(1): e0115237.). For analysis three slides/animal and \leq five individual sections/slide were assessed. Sections carrying tissue artifacts or aberrant staining were excluded. To assess the number of A β -positive vessels, 3A5 stained sections (3 slides/animal covering cortex and hippocampus and up to five individual sections per slide) have been analysed. A β -positive vessels were manually counted in sub-regions of the cortex as well as in the hippocampus. Number of positive vessels per mm² was determined.

References:

- Rogers et al., Behav Brain Res 105 (1999): 207-217.
Mandler et al., PLoS ONE 10(1) (2015): e0115237.
doi:10.1371/journal.pone.0115237.
Mandler et al., J Alzheimers Dis 28: 783-794.
Comery et al., J Neurosci 25 (2005): 8898-8902.

Results:

To test the immunogenicity of two A β targeting vaccines SeqID 1-KLH-Alum and SeqID 2-KLH Alum in comparison to KLH-Alum and Alum (Aluminium-oxyhydroxide) only, Tg2576-mice were injected 6x, s.c., at 4-week intervals with either conjugate-vaccine containing 30 μ g net peptide, equivalent doses of KLH formulated with Alum or Alum only. Alum doses used were equivalent to 2mg/ml. Vaccination induced Abs were measured in plasma samples

taken at sacrifice (SeqID 1 (n=10), SeqID 2 (n=8), KLH-Alum (n=10) and Alum only (n=8)). All 3 vaccines elicited strong and comparable IgG titers towards the peptide used for immunization (Fig 6A). Alum only did not elicit signals above background (Fig 6A). Both A β targeting vaccines, SeqID 1-KLH-Alum and SeqID 2-KLH-Alum, elicited Abs to human A β whereas KLH-Alum vaccine and Alum only did not elicit signals above background in treated animals (Fig 6B).

To evaluate the effect of Aluminum-oxyhydroxide only (Alum) in comparison to A β targeting vaccines (SeqID 1- + SeqID 2-KLH-Alum) and non A β specific vaccines (KLH-Alum) on cognitive functions, we applied Contextual Fear Conditioning (CFC) analyzing contextual memory and learning in Tg2576-mice. As expected, CFC demonstrated that SeqID 1- and SeqID 2-treated mice were superior to control animals receiving KLH-Alum (thus not eliciting an A β specific immune response) in this AD model of A β deposition (Fig. 7). Interestingly, animals receiving Alum only, (without a conjugate eliciting an active immune response against KLH or A β , respectively), showed similar effects as detectable with A β targeting vaccines in this AD model in the absence of A β -specific antibodies.

To test whether Alum would also significantly influence cerebral amyloid load, animals undergoing CFC were subsequently sacrificed at 14 months of age. Their brains were assessed for diffuse and dense-cored plaques by IF-staining using monoclonal antibody 3A5. Cortical as well as hippocampal sections of KLH/ALUM-injected controls were covered by numerous amyloid plaques (Fig.8A+C). By contrast, respective brain areas of SeqID 1- and SeqID 2-immunized Tg2576-mice contained significantly less deposits (Fig. 8B+D and E, $p < 0.05$ and data not shown). Importantly, treatment of Tg2576 animals with Alum only did not significantly alter amyloid deposition as compared to KLH-Alum treated animals (Fig.8 E) in this AD model.

Thus, Figs. 7 and 8 also disclose that topically applied aluminium-oxyhydroxide is able to lower cognitive decline significantly in an APP-transgenic model for Alzheimer's disease (Tg2576) without significantly changing cerebral A β levels. This is implying an APP/A β independent mechanism underlying beneficial functional effects exerted by aluminium-oxyhydroxide in

this AD model and further evidences the lack of scientific plausibility of the "amyloid channel hypothesis".

Claims:

1. Method for the treatment of Alzheimer's Disease (AD), wherein an immune stimulating pharmaceutical composition comprising an aluminium salt is administered to a patient having AD or having a risk to develop AD in an effective amount.
2. Method according to claim 1, wherein the aluminium salt has the general formula $\text{Me}_a^+ \text{Al}_b^{3+} \text{An}^{c-} \cdot n\text{H}_2\text{O}$, wherein
 Me^+ is Na^+ , K^+ , Li^+ , Rb^+ , Cs^+ or NH_4^+ ;
 An is PO_4^{3-} , SO_4^{2-} , $\text{O}(\text{OH})^{3-}$, O_2^- or OH^- ;
 a is 0, 1, 2, or 3;
 b is 1 or 2;
 c is 1, 2, 3, 4, 5, or 6; and
 n is 0 to 48.
3. Method according to claim 1 or 2, wherein the aluminium salt is selected from aluminium hydroxide, aluminium oxyhydroxide, aluminium phosphate, or aluminium sulphate.
4. Method according to any one of claims 1 to 3 wherein the aluminium salt is administered as the single effective ingredient in said immune stimulating pharmaceutical composition.
5. Method according to any one of claims 1 to 4, wherein the immune stimulating pharmaceutical composition comprises auxiliary substances, especially stabilisators, detergents, antioxidants, complexing agents for mono- or divalent metal ions, carbohydrates and/or buffer substances.
6. Method according to any one of claims 1 to 5, wherein the immune stimulating pharmaceutical composition is liquid and has a pH of 5 to 9, preferably of 5.5 to 8.0.
7. Method according to any one of claims 1 to 6, wherein the immune stimulating pharmaceutical composition is liquid and has a pH of 6 to 7.5.
8. Method according to any one of claims 1 to 7, wherein the aluminium salt is an aluminium oxyhydroxide suspension, preferably

European Pharmacopoeia grade aluminium-oxyhydroxide (monograph 1664), especially Alhydrogel.

9. Method according to any one of claims 1 to 8, wherein the aluminium salt is aluminium oxyhydroxide and is administered in an amount of at least 1.2 mg (given as Al_2O_3 equivalent) to an AD patient.

10. Method according to any one of claims 1 to 9, wherein the aluminium salt is aluminium oxyhydroxide, especially Alhydrogel, and wherein the effective amount is between 1.5 and 4 mg aluminium oxyhydroxide, especially Alhydrogel, per application, especially per dose.

11. Method according to claim 10, wherein the application is an injection, especially a double or triple injection at about the same injection site.

12. Method according to claim 11, wherein the same injection site is defined as being within an area of 10 cm^2 of the skin, preferably within 5 cm^2 of the skin, especially within 1 cm^2 of the skin.

13. Method according to any one of claims 10 to 12, wherein the aluminium salt is administered to a patient in two or three doses within two days and in an amount of at least 1.2 mg of at least one dose.

14. Method according to any one of claims 1 to 13, wherein the aluminium salt is administered to a patient at least once monthly in an amount of at least 1.5 mg.

15. Method according to any one of claims 1 to 14, wherein the aluminium salt is administered to a patient at least once monthly for a duration of at least three months, preferably of at least six months, especially for at least one year, in an amount of at least 1.5 mg.

16. Method according to any one of claims 1 to 15, wherein the aluminium salt is administered to a patient at least once month-

ly for a duration of at least one year, preferably of at least three years, especially for at least five years, in an amount of at least 1.5 mg.

17. Method according to any one of claims 1 to 16, wherein the aluminium salt is administered to a patient at least once monthly for a duration of at least three months, preferably of at least six months, especially for at least one year, in an amount of at least 1.8 mg, preferably in an amount of 1.8 to 2.5 mg, especially of about 2.0 mg.

18. Method according to any one of claims 1 to 17, wherein the aluminium salt is administered to a patient at least twice monthly for a duration of at least one month, preferably of at least two months, especially for at least one year, in an amount of at least 1.8 mg, preferably in an amount of 1.8 to 2.5 mg, especially of about 2.0 mg.

19. Method according to any one of claims 1 to 17, wherein the aluminium salt is administered to a patient at least four times monthly for a duration of at least one month, preferably of at least two months, especially for at least one year, in an amount of at least 1.0 mg, preferably in an amount of 1.2 to 3 mg, especially of 1.5 to 2.5 mg.

20. Method according to any one of claims 1 to 19, wherein the aluminium salt is administered to a patient at least twice within one week at about the same injection site, in an amount of at least 1.0 mg, preferably in an amount of 1.2 to 3 mg, especially of 1.5 to 2.5 mg.

21. Method according to any one of claims 1 to 20, wherein the aluminium salt is aluminium oxyhydroxide and is administered in an amount of 1.2 mg to 5.0 mg to an AD patient.

22. Method according to any one of claims 1 to 21, wherein the aluminium salt is aluminium oxyhydroxide and is administered in an amount of at least 1.5 mg to an AD patient.

23. Method according to any one of claims 1 to 22, wherein the

aluminium salt is aluminium oxyhydroxide and additionally contains one or more stabilisators, especially thiomersal, detergents, antioxidants, complexing agents for mono- or divalent metal ions, especially ethylenediaminetetraacetic acid (EDTA), sugars, sugar alcohols, glycerol, and/or buffer substances, especially TRIS or phosphate buffer substances.

24. Method according to any one of claims 1 to 17 wherein the aluminium salt is aluminium oxyhydroxide and is administered to a patient in a suspension with a pH of 4 to 10, preferably of 5 to 9, more preferred of 6 to 8, especially from 7.0 to 7.5.

25. Method according to any one of claims 1 to 24 wherein the aluminium salt is aluminium oxyhydroxide and is administered to a patient in an isotonic suspension.

26. Method according to any one of claims 1 to 25, wherein the aluminium salt is aluminium oxyhydroxide and is administered subcutaneously, intranodally, intradermally, or intramuscularly, especially subcutaneously, to an AD patient.

27. Method according to any one of claims 1 to 26, wherein the aluminium salt is aluminium oxyhydroxide and is administered at least once monthly for at least two months to an AD patient.

28. Method according to any one of claims 1 to 27, wherein the aluminium salt is aluminium oxyhydroxide and is administered at least once monthly for at least six months to an AD patient.

29. Method according to any one of claims 1 to 28, wherein the aluminium salt is aluminium oxyhydroxide and is administered at least twice a month for at least six months, preferably for at least twelve months, especially at least 24 months, to an AD patient.

30. Method according to any one of claims 1 to 29, wherein the aluminium salt is aluminium oxyhydroxide and is administered to an AD patient subcutaneously in the upper arm, preferably alternating in the left and in the right upper arm.

31. Method according to any one of claims 1 to 30, wherein the aluminium salt is aluminium oxyhydroxide and is administered in split doses to an AD patient, especially at the same site of administration.

32. Method according to any one of claims 1 to 31, wherein the aluminium salt is aluminium oxyhydroxide and is administered in split doses of 0.8 to 5.0 mg, preferably of 1.0 to 3.0, especially from 1.0 to 1.5 mg, to an AD patient.

33. Method according to any one of claims 1 to 32, wherein the aluminium salt is aluminium oxyhydroxide and is administered at least monthly for at least two years, preferably at least four years, especially at least 8 years, to an AD patient.

34. Method according to any one of claims 1 to 33, wherein the aluminium salt is aluminium oxyhydroxide and is administered by an injection device, especially a syringe, to an AD patient.

35. Method according to any one of claims 1 to 34, wherein the aluminium salt is aluminium oxyhydroxide and is administered in an amount of at least 1.8 mg to an AD patient.

36. Method according to any one of claims 1 to 35, wherein the aluminium salt is preferably aluminium oxyhydroxide and is administered to the AD patient in liquid form in an application volume of 0.1 to 10 ml, preferably of 0.2 to 5 ml, especially of 0.4 to 3 ml.


37. Method according to any one of claims 1 to 36 contained in a pharmaceutical preparation, wherein said preparation is devoid of sulphate, nitrate, or chloride anions.

38. Method according to any one of claims 1 to 37 contained in a pharmaceutical preparation, wherein said preparation has a heavy metal content of less than 20 ppm.

39. Method according to any one of claims 1 to 38 contained in a pharmaceutical preparation, wherein said preparation is a suspension of aluminium oxyhydroxide and has a particle size dis-

tribution between 2 μm and approximately 10 μm , said particles being aggregates, composed of smaller fibers of preferably about 2 nm x 4.5 nm x 10nm.

Figure 1







Figure 2

Figure 3



4/8

Figure 4





Figure 5






Figure 6 A




Figure 6 B





Figure 7

Figure 8



INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2015/059337

A. CLASSIFICATION OF SUBJECT MATTER INV. A61K38/03 A61K39/39 A61K33/06 A61P25/28 ADD.											
According to International Patent Classification (IPC) or to both national classification and IPC											
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) A61K A61P Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) EPO-Internal, WPI Data, BIOSIS, EMBASE, CHEM ABS Data											
C. DOCUMENTS CONSIDERED TO BE RELEVANT <table border="1"> <thead> <tr> <th>Category*</th> <th>Citation of document, with indication, where appropriate, of the relevant passages</th> <th>Relevant to claim No.</th> </tr> </thead> <tbody> <tr> <td>X</td> <td>WO 94/16327 A1 (POLLARD HARVEY B [US]; ARISPE NELSON [US]; ROJAS EDWARDS [US]) 21 July 1994 (1994-07-21) page 29, line 6; claims 6,8,12,25-27 page 26, line 1 - page 27, line 5 -----</td> <td>1-4,37, 38</td> </tr> <tr> <td>X</td> <td>EP 2 659 908 A1 (AFFIRIS AG [AT]) 6 November 2013 (2013-11-06) paragraphs [0035], [0037], [0047], [0048]; claims 1,3,6 ----- -/-</td> <td>1-3,5,8, 11,23, 26-29, 34,37,38</td> </tr> </tbody> </table>			Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	X	WO 94/16327 A1 (POLLARD HARVEY B [US]; ARISPE NELSON [US]; ROJAS EDWARDS [US]) 21 July 1994 (1994-07-21) page 29, line 6; claims 6,8,12,25-27 page 26, line 1 - page 27, line 5 -----	1-4,37, 38	X	EP 2 659 908 A1 (AFFIRIS AG [AT]) 6 November 2013 (2013-11-06) paragraphs [0035], [0037], [0047], [0048]; claims 1,3,6 ----- -/-	1-3,5,8, 11,23, 26-29, 34,37,38
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.									
X	WO 94/16327 A1 (POLLARD HARVEY B [US]; ARISPE NELSON [US]; ROJAS EDWARDS [US]) 21 July 1994 (1994-07-21) page 29, line 6; claims 6,8,12,25-27 page 26, line 1 - page 27, line 5 -----	1-4,37, 38									
X	EP 2 659 908 A1 (AFFIRIS AG [AT]) 6 November 2013 (2013-11-06) paragraphs [0035], [0037], [0047], [0048]; claims 1,3,6 ----- -/-	1-3,5,8, 11,23, 26-29, 34,37,38									
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.											
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family											
Date of the actual completion of the international search		Date of mailing of the international search report									
15 July 2015		21/07/2015									
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016		Authorized officer Allnutt, Sarah									

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2015/059337

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 2011/120924 A1 (NOVARTIS AG [CH]; ULRICH PETER [CH]; BAER KATJA [CH]; IMBERT GEORGES []) 6 October 2011 (2011-10-06)</p> <p>page 6, paragraph 5; claims 1,7,9,12,16,17; example 3 page 7, paragraph 2 page 17, paragraph 4; example 1</p> <p>-----</p>	<p>1-3,5-8, 11,23, 24,26, 30,34, 36-38</p>
Y	<p>MICHAEL T. HENKA ET AL: "NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice", NATURE, vol. 493, no. 7434, 19 December 2012 (2012-12-19), pages 674-678, XP055125448, ISSN: 0028-0836, DOI: 10.1038/nature11729 abstract</p> <p>-----</p>	<p>1-39</p>
Y	<p>AIMANIANDA V ET AL: "Novel cellular and molecular mechanisms of induction of immune responses by aluminum adjuvants", TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER, HAYWARTH, GB, vol. 30, no. 6, 1 June 2009 (2009-06-01), pages 287-295, XP026170830, ISSN: 0165-6147, DOI: 10.1016/J.TIPS.2009.03.005 [retrieved on 2009-05-11] abstract</p> <p>-----</p>	<p>1-39</p>
X	<p>WO 2006/005707 A2 (MATTNER FRANK [AT]; SCHMIDT WALTER [AT]) 19 January 2006 (2006-01-19) Peptide 4002; claims 1,4; table 2</p> <p>-----</p>	<p>1-3,5,8, 23</p>
X	<p>WO 2009/149485 A2 (AFFIRIS AG [AT]; MANDLER MARKUS [AT]; SANTIC RADMILA [AT]; WENINGER HA) 17 December 2009 (2009-12-17)</p> <p>page 26 - page 27; claims 3,4,9,13 page 23, paragraph 1</p> <p>-----</p>	<p>1-3,5,8, 11,23, 26-28, 37,38</p>
X	<p>WO 2009/149486 A2 (AFFIRIS AG [AT]; MANDLER MARKUS [AT]; GIEFFERS CHRISTIAN [DE]; MATTNER) 17 December 2009 (2009-12-17) page 33 - page 35; claims 6,9-12; table 2c page 29, paragraph 2</p> <p>-----</p> <p>-/--</p>	<p>1-3,5,8, 11,23, 26-28, 37,38</p>

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2015/059337

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 99/27944 A1 (ATHENA NEUROSCIENCES INC [US]; SCHENK DALE B [US]) 10 June 1999 (1999-06-10) page 61, paragraph 2; figure 14; examples VII,IX,; table 7 page 71, paragraph 1 -----	1-39

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2015/059337

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 9416327	A1	21-07-1994	AU	3440593 A		15-08-1994
			WO	9416327 A1		21-07-1994

EP 2659908	A1	06-11-2013	EP	2659908 A1		06-11-2013
			TW	201345927 A		16-11-2013
			WO	2013164357 A1		07-11-2013

WO 2011120924	A1	06-10-2011	AR	080810 A1		09-05-2012
			AU	2011234656 A1		11-10-2012
			CA	2793580 A1		06-10-2011
			CL	2012002685 A1		25-01-2013
			CN	102834118 A		19-12-2012
			CN	104436212 A		25-03-2015
			CO	6630127 A2		01-03-2013
			EC	SP12012180 A		30-10-2012
			EP	2552489 A1		06-02-2013
			GT	201200265 A		14-03-2014
			JP	2013523682 A		17-06-2013
			KR	20130018407 A		21-02-2013
			MA	34084 B1		05-03-2013
			NZ	601729 A		25-10-2013
			PE	06422013 A1		19-06-2013
			RU	2012145734 A		10-05-2014
			SG	183806 A1		30-10-2012
			TW	201138805 A		16-11-2011
			US	2013011431 A1		10-01-2013
			US	2014348871 A1		27-11-2014
			WO	2011120924 A1		06-10-2011

WO 2006005707	A2	19-01-2006	AT	413946 B		15-07-2006
			AU	2005261688 A1		19-01-2006
			CA	2573424 A1		19-01-2006
			CN	101043901 A		26-09-2007
			CN	103263664 A		28-08-2013
			EP	1765390 A2		28-03-2007
			JP	5179866 B2		10-04-2013
			JP	2008506666 A		06-03-2008
			KR	20070032033 A		20-03-2007
			TW	I353848 B		11-12-2011
			US	2009004210 A1		01-01-2009
			WO	2006005707 A2		19-01-2006

WO 2009149485	A2	17-12-2009	AT	506820 A1		15-12-2009
			AT	509611 A1		15-10-2011
			AU	2009257168 A1		17-12-2009
			CA	2723967 A1		17-12-2009
			CN	102123728 A		13-07-2011
			EP	2310033 A2		20-04-2011
			ES	2392789 T3		13-12-2012
			JP	2011522840 A		04-08-2011
			JP	2014139227 A		31-07-2014
			KR	20110036039 A		06-04-2011
			RU	2011100125 A		20-07-2012
			US	2011171243 A1		14-07-2011
			WO	2009149485 A2		17-12-2009

WO 2009149486	A2	17-12-2009	AT	506819 A1		15-12-2009
			AT	509105 A1		15-06-2011

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2015/059337

Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
		AT 509106 A1	15-06-2011	
		AU 2009257169 A1	17-12-2009	
		CA 2723991 A1	17-12-2009	
		CN 102123727 A	13-07-2011	
		DK 2310034 T3	28-04-2014	
		EP 2310034 A2	20-04-2011	
		ES 2461492 T3	20-05-2014	
		HK 1152470 A1	29-08-2014	
		HR P20140586 T1	12-09-2014	
		JP 2011522841 A	04-08-2011	
		KR 20110036808 A	11-04-2011	
		PT 2310034 E	05-06-2014	
		RS 53236 B	29-08-2014	
		RU 2011100126 A	20-07-2012	
		SI 2310034 T1	30-05-2014	
		US 2011097351 A1	28-04-2011	
		US 2013230545 A1	05-09-2013	
		WO 2009149486 A2	17-12-2009	

WO 9927944	A1	10-06-1999	AR 020050 A1	10-04-2002
			AT 399016 T	15-07-2008
			AT 433760 T	15-07-2009
			AT 435659 T	15-07-2009
			AT 493149 T	15-01-2011
			AU 1706199 A	16-06-1999
			BR 9815357 A	24-10-2000
			CA 2312920 A1	10-06-1999
			CN 1281366 A	24-01-2001
			CO 4980846 A1	27-11-2000
			CY 1108331 T1	12-02-2014
			CY 1109368 T1	02-07-2014
			CZ 20001706 A3	15-11-2000
			DE 1033996 T1	07-06-2001
			DE 06075479 T1	16-11-2006
			DE 06075704 T1	28-12-2006
			DK 1033996 T3	22-09-2008
			DK 1679080 T3	28-09-2009
			DK 1994937 T3	07-02-2011
			DK 2305282 T3	07-10-2013
			EA 200601132 A1	27-02-2007
			EE 2000000379 A	16-04-2001
			EP 1033996 A1	13-09-2000
			EP 1679080 A2	12-07-2006
			EP 1690547 A1	16-08-2006
			EP 1994937 A2	26-11-2008
			EP 2305282 A2	06-04-2011
			ES 2262460 T1	01-12-2006
			ES 2263408 T1	16-12-2006
			ES 2310017 T3	16-12-2008
			ES 2428740 T3	11-11-2013
			GE P20043319 B	10-05-2004
			GE P20053715 B	26-12-2005
			HK 1094535 A1	31-12-2009
			HK 1095265 A1	19-03-2010
			HR P20000443 A2	31-10-2000
			HR P20090568 A2	30-06-2010
			HU 228493 B1	28-03-2013
			HU 0100627 A2	28-06-2001

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2015/059337

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
	ID	25504 A	05-10-2000
	IL	136252 A	30-11-2010
	IL	191904 A	28-05-2014
	IS	5500 A	17-05-2000
	JP	4677094 B2	27-04-2011
	JP	4677333 B2	27-04-2011
	JP	4677334 B2	27-04-2011
	JP	2002502802 A	29-01-2002
	JP	2006077030 A	23-03-2006
	JP	2006131639 A	25-05-2006
	JP	2010215651 A	30-09-2010
	KR	100936419 B1	12-01-2010
	KR	20090078366 A	17-07-2009
	KR	20120135915 A	17-12-2012
	MY	134906 A	31-12-2007
	NO	331425 B1	27-12-2011
	NO	332813 B1	21-01-2013
	NO	20002784 A	31-07-2000
	NZ	504569 A	28-01-2005
	PE	13832000 A1	25-11-2000
	PL	202698 B1	31-07-2009
	PL	202706 B1	31-07-2009
	PL	342649 A1	18-06-2001
	PT	1033996 E	02-10-2008
	PT	1679080 E	10-09-2009
	PT	1994937 E	22-02-2011
	PT	2305282 E	27-09-2013
	SG	111083 A1	30-05-2005
	SI	1033996 T1	28-02-2009
	SI	1679080 T1	31-12-2009
	SI	1994937 T1	29-04-2011
	SI	2305282 T1	30-10-2013
	TR	200001608 T2	23-07-2001
	TW	I239847 B	21-09-2005
	US	2004170641 A1	02-09-2004
	US	2004171815 A1	02-09-2004
	US	2004171816 A1	02-09-2004
	US	2004228865 A1	18-11-2004
	US	2005013815 A1	20-01-2005
	US	2005019330 A1	27-01-2005
	US	2005019343 A1	27-01-2005
	US	2005031629 A1	10-02-2005
	US	2005037026 A1	17-02-2005
	US	2005048049 A1	03-03-2005
	US	2005142132 A1	30-06-2005
	US	2005163788 A1	28-07-2005
	US	2005191292 A1	01-09-2005
	US	2005191314 A1	01-09-2005
	US	2005196399 A1	08-09-2005
	US	2005249725 A1	10-11-2005
	US	2005249727 A1	10-11-2005
	US	2006029611 A1	09-02-2006
	US	2006034858 A1	16-02-2006
	US	2008096818 A1	24-04-2008
	US	2008227718 A1	18-09-2008
	US	2008227719 A1	18-09-2008
	US	2009191231 A1	30-07-2009
	US	2012276116 A1	01-11-2012

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2015/059337

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		US 2013058869 A1	07-03-2013
		US 2014227274 A1	14-08-2014
		WO 9927944 A1	10-06-1999
